Meeting
2019 Gastrointestinal Cancers Symposium
The prognostic value of systemic inflammatory factors in BRAF (V600E) mutant metastatic colorectal cancer (mCRC).
Authors
Nieves Martinez Lago
Hospital Clinico de Santiago de Compostela, Santiago De Compostela, Spain
Nieves Martinez Lago , Marta Covela Rúa , Elena Brozos Vazquez , Ana Fernandez Fernandez Montes , Juan Cruz de la Cámara Gómez , Carlos Méndez Méndez , Mónica Jorge Fernández , Antia Cousillas Castiñeira , Begoña Graña Suárez , Guillermo Alfonso Quintero Aldana , Sonia Candamio Folgar , Mercedes Salgado Fernandez , Maria Luz Pellon Augusto , Paula Gonzalez Villarroel , Elena Gallardo Martin , Marta Carmona Campos , Francisca Vazquez Rivera , Carlos Grande Ventura , Alberto Carral Maseda , Margarita Reboredo Lopez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 622)
DOI
10.1200/JCO.2019.37.4_suppl.622
Abstract #
622
Poster Bd #
K7
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study).
First Author: Akihisa Matsuda
Poster
2018 ASCO Annual Meeting
The value of inflammatory markers in predicting overall survival in older adults with cancer.
First Author: Tomohiro F. Nishijima
Poster
2018 Gastrointestinal Cancers Symposium
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.
First Author: Stephen John Clarke
Poster
2017 ASCO Annual Meeting
Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.
First Author: Thomas Powles